Navigation Links
Newer Rheumatoid Arthritis Drugs Don't Raise Cancer Risk: Study
Date:9/6/2012

THURSDAY, Sept. 6 (HealthDay News) -- A new review finds that rheumatoid arthritis medications known as biologics don't raise the risk of cancer, contrary to what some previous research has suggested.

Rheumatoid arthritis affects an estimated 1 percent of the general population, with women three times more likely to have it. Different from age-related osteoarthritis, rheumatoid arthritis is debilitating autoimmune disorder that causes inflammation of the lining of the joints.

Biologics work by targeting specific parts of the immune system involved in the inflammation process.

Previous studies have raised questions about whether the drugs might boost the risk of cancer. The new study appears in the Sept. 5 issue of the Journal of the American Medical Association.

The researchers, led by a researcher at the University of Texas M.D. Anderson Cancer Center, looked at 63 randomized controlled trials of the drugs that featured follow-up periods of at least 24 weeks. In total, the studies analyzed nearly 29,500 patients.

The biologic medications are abatacept (Orencia), adalimumab (Humira), anakinra (Kineret), certolizumab (Cimzia), etanercept (Enbrel), golimumab (Simponi), infliximab (Remicade), rituximab (Rituxan), and tocilizumab (Actemra).

The analysis didn't find any extra risk of cancer compared to other drugs for rheumatic arthritis or a placebo.

The drugs are commonly used to treat rheumatoid arthritis, said Dr. Nadera Sweiss, an associate professor of medicine at the University of Illinois at Chicago College of Medicine who was not involved with the study.

"Biologic therapy revolutionized the treatment of [rheumatoid arthritis]," she said, and explained that these drugs are "introduced earlier in the disease course to control inflammatory activity early on and decrease the risk of disability."

Fear of cancer, however, has been a major issue for patients, she said, especially in those who may need to be on the medications for life.

As for the new analysis, she praised it but said it's limited because it examines the effect of the drugs up to 24 weeks. "There is still a concern about long-term safety," she said.

More information:

For more about rheumatoid arthritis, try the U.S. National Library of Medicine.

-- Randy Dotinga

SOURCES: Nadera Sweiss, M.D., associate professor, medicine, University of Illinois at Chicago College of Medicine; Sept. 5, 2012, Journal of the American Medical Association


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Newer Antidepressants May Be Safe for Parkinsons Patients
2. Newer Second-Line Diabetes Drug May Outperform Older Meds
3. Law Firm Aggressively Litigating against Birth Control Makers for their Newer, but Allegedly Unsafer Products: Nuvaring, Yaz, BeYaz, Yasmin, Ocella, Gianvi
4. Newer technology to control blood sugar works better than conventional methods
5. Newer hip reconstruction technique provides good outcomes for athletes
6. Newer Bone Drug Better for Advanced Breast Cancer Patients: Study
7. Older Antipsychotics May Work as Well as Newer Ones: Review
8. Newer Psoriasis Drugs May Lower Heart Attack Risk for Patients
9. Newer Drug-Releasing Stent Cuts Chances of Cardiac Events: Study
10. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
11. Treat Rheumatoid Arthritis Early and Aggressively: Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newer Rheumatoid Arthritis Drugs Don't Raise Cancer Risk: Study
(Date:1/16/2017)... ... January 17, 2017 , ... Recently, patients and staff from A ... other volunteers and organizations in support of the annual Binder Park Zoo Halloween celebration ... up in colorful costumes of all designs coming out to enjoy games, face painting, ...
(Date:1/16/2017)... ... ... Anybody who may be looking for a substance abuse rehabilitation program with ... a holistic treatment center for addiction located in Marne, MI. This video, which can ... and staff that visited the 2016 Recovery Palooza support event in nearby Grand Rapids. ...
(Date:1/16/2017)... ... January 16, 2017 , ... Atlanta-based incentive company ... in the wheelchair accessibility industry, BraunAbility . Incentive Solutions will provide BraunAbility ... accessible vehicles. With this new incentive plan, BraunAbility plans to continue their tradition ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... One thing ... only to treat, but to test for, as well. The money spent screening for ... year.(1) Doctors in the U.S. screen patients for cancer more than in any other ...
(Date:1/15/2017)... ... 15, 2017 , ... Going above and beyond the practical ... better communities around the world by offering the Gensuite team and their services ... team members to become involved in a cause that is bigger than themselves ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... TORONTO , Jan. 16, 2017 When synthetic ... to market their product as top-rate. They offered free samples, ... top-notch customer service. Soon, business was booming. ... often described as 100 times more powerful than morphine, has ... in last 2 years. One dealer,s recorded fentanyl ...
(Date:1/16/2017)... PUNE, India , January 16, 2017 /PRNewswire/ ... Research, titled, "Vital Signs Monitoring Devices Market by Type and ... that the global vital signs monitoring devices market size was ... $5,491 million by 2022, growing at a CAGR of 5.8% ... was the leading regional market in global vital signs monitoring ...
(Date:1/16/2017)... PUNE, India , January 16, 2017 ... & Its Derivatives Market by Product Type (Methyl, ... Personal Care, Foods & Beverages, Surface Coatings ... 2021", published by MarketsandMarkets, the market was ... and is projected to reach USD 6.41 ...
Breaking Medicine Technology: